Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate [Seeking Alpha]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Seeking Alpha
Taletrectinib has shown promising clinical activity in treating ROS1-positive non-small cell lung cancer and has Breakthrough Therapy Designation. Nuvation Bio also now has other pipeline candidates, including safusidenib and NUV-868, and has sufficient liquid assets to fund operations for years without help. Topline Summary Nuvation Bio ( NYSE: NUVB ) is an early-stage developmental biotech focused on pushing forward therapies for different types of cancer. At this time, they have a few agents in the pipeline, both in phase 1 study. With the recent news that they've acquired a more advanced pipeline candidate, the company has surged to a market cap approaching $1 billion. In this article, I want to share some thoughts on the prospects of their current pipeline, what this new drug is (spoiler alert for those in the know: it's taletrectinib), and how their financial status is shaping up to move forward. Nuvation Bio Pipeline Overview Taletrectinib If you go on the website
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingBusiness Wire
- Nuvation Bio Completes Acquisition of AnHeart Therapeutics [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio Completes Acquisition of AnHeart TherapeuticsBusiness Wire
- Week In Review: AriBio Sells China Rights To Alzheimer's Candidate In $770M Deal [Seeking Alpha]Seeking Alpha
NUVB
Earnings
- 11/2/23 - Beat
NUVB
Sec Filings
- 4/26/24 - Form 10-K/A
- 4/18/24 - Form S-8
- 4/11/24 - Form 4
- NUVB's page on the SEC website